Serina Therapeutics

SER

Biotechnology · Healthcare

Price

$2.87

+0.22 (+8.30%)

Market Cap

$43.0M

Exchange

New York Stock Exchange American

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+845.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 1.1M (2021) → 10.2M (2025)

Winston Score History

The full picture

Serina Therapeutics is a small biotechnology company focused on developing new treatments for neurological diseases, particularly Parkinson's disease. Its core technology is a drug delivery platform called POZ, which is designed to make existing drugs work better and last longer in the body. The company is in early-stage research and does not yet sell any approved products.

Serina makes no commercial revenue today and funds its work through grants, partnerships, and capital raises — typical for a pre-revenue biotech. It operates primarily in the United States and is a very small company with a market cap near zero, meaning it carries significant financial risk. The main growth driver would be advancing its lead drug candidate through clinical trials and eventually gaining regulatory approval, but the main risk is that it could run out of funding before reaching that milestone.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-100.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+14.1% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$13M/ year

↑ Rising (+76% vs prior year)

R&D investment increasing — building for the future

Insider Activity

66.9%ownership

Insiders own a meaningful stake in the company

Cash Runway

~10 months

$23M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Serina Therapeutics has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

Data not available

Profit after running costs

Operating Margin

N/A

Data not available

Return on the money invested

ROCE

-136.1%

Weak — -136.1% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-100.0%

Shrinking sales (-100.0% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.01

Conservative — low debt load (0.01)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial